Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel

Abstract Background Trastuzumab, pertuzumab, and docetaxel (THP) have represented the standard first-line treatment for HER2-positive metastatic breast cancer (MBC) for over a decade, following the pivotal CLEOPATRA trial. However, interim results from the DESTINY-Breast09 trial suggest that trastuz...

Descripció completa

Dades bibliogràfiques

Autors principals:	Marcin Kubeczko, Andrea d’Amico, Olgierd Chrabanski, Daria Handkiewicz-Junak, Anna Polakiewicz-Gilowska, Katarzyna Swiderska, Marta Mianowska-Malec, Aleksandra Lesniak, Barbarba Lanoszka, Natalya Lisovska, Damian Borys, Bartlomiej Pycinski, Ewa Chmielik, Slawomir Blamek, Aleix Prat, Michal Jarzab
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-12-01
Col·lecció:	Breast Cancer Research
Matèries:	FDG PET/CT HER2-positive metastatic breast cancer SUVmax Trastuzumab-pertuzumab-docetaxel Biomarker
Accés en línia:	https://doi.org/10.1186/s13058-025-02191-7
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!